Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dolutegravir Passes Late Pregnancy Test

Publish date:: April 12, 2019

Key clinical point: Faster acting integrase inhibitors have the potential to accelerate reduction of viral load.

Major finding: Three-quarters of patients achieved viral load less than 50 copies/mL at delivery with dolutegravir, compared with 43% receiving efavirenz.

Study details: A randomized, controlled trial (n = 268).

Disclosures: The study was funded by the University of Liverpool. Dr. Khoo reported consulting for and receiving research funding from ViiV.

Citation:

Khoo S et al. CROI 2019, Abstract 40 LB.

This Week's Must Reads

Educational intervention curbs use of antibiotics for respiratory infections,

Many children with COVID-19 present without classic symptoms,

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

ACS disagrees with CDC on HPV vaccination in adults,

More data needed to better understand COVID-19 skin manifestations,

Must Reads in HIV

Neural tube defect risk from dolutegravir drops as clinical experience grows,

MCC response varies based on immunosuppression type, especially CLL,

Evolocumab safe, well-tolerated in HIV+ patients,

Should ART for HIV be initiated prior to tuberculosis testing results?,

Bone density slow to rebound after lactation in women with HIV,

Infectious Disease

Infectious Disease

Dolutegravir Passes Late Pregnancy Test

This Week's Must Reads

Must Reads in HIV